CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.05 (-2.27%)
Close on Nov 17, 2026Market cap $422.73MP/E –Yield –
CytomX Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
CytomX Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $18.30M, down 87.0% year over year. For fiscal 2025 it was $76.20M, down 44.8% from the year before. Over ten years it grew 25.7% a year on average. The highest annual figure on record is $138.10M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.20M | -44.8% |
| FY2024 | Dec 31, 2024 | $138.10M | +36.4% |
| FY2023 | Dec 31, 2023 | $101.21M | +90.4% |
| FY2022 | Dec 31, 2022 | $53.16M | +42.5% |
| FY2021 | Dec 31, 2021 | $37.31M | -45.5% |
| FY2020 | Dec 31, 2020 | $68.43M | +154.4% |
| FY2019 | Dec 31, 2019 | $26.90M | -54.8% |
| FY2018 | Dec 31, 2018 | $59.50M | -16.9% |
| FY2017 | Dec 31, 2017 | $71.62M | +376.1% |
| FY2016 | Dec 31, 2016 | $15.04M | +95.1% |
| FY2015 | Dec 31, 2015 | $7.71M | +51.9% |
| FY2014 | Dec 31, 2014 | $5.08M | +471.7% |
| FY2013 | Dec 31, 2013 | $888.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.42M | -92.4% |
| Q1 FY2026 | Mar 31, 2026 | $10.26M | -79.9% |
| Q4 FY2025 | Dec 31, 2025 | $663.00K | -98.3% |
| Q3 FY2025 | Sep 30, 2025 | $5.96M | -82.2% |
| Q2 FY2025 | Jun 30, 2025 | $18.66M | -25.7% |
| Q1 FY2025 | Mar 31, 2025 | $50.92M | +22.8% |
| Q4 FY2024 | Dec 31, 2024 | $38.09M | +43.2% |
| Q3 FY2024 | Sep 30, 2024 | $33.43M | +26.7% |
| Q2 FY2024 | Jun 30, 2024 | $25.12M | +1.6% |
| Q1 FY2024 | Mar 31, 2024 | $41.46M | +76.4% |
| Q4 FY2023 | Dec 31, 2023 | $26.61M | +32.2% |
| Q3 FY2023 | Sep 30, 2023 | $26.38M | +136.7% |
| Q2 FY2023 | Jun 30, 2023 | $24.72M | +92.4% |
| Q1 FY2023 | Mar 31, 2023 | $23.50M | +159.9% |
| Q4 FY2022 | Dec 31, 2022 | $20.12M | +80.8% |
| Q3 FY2022 | Sep 30, 2022 | $11.15M | +21.3% |
| Q2 FY2022 | Jun 30, 2022 | $12.85M | +46.1% |
| Q1 FY2022 | Mar 31, 2022 | $9.04M | +10.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.13M | +57.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.19M | +23.1% |
| Q2 FY2021 | Jun 30, 2021 | $8.80M | +25.9% |
| Q1 FY2021 | Mar 31, 2021 | $8.20M | -82.5% |
| Q4 FY2020 | Dec 31, 2020 | $7.08M | -14.5% |
| Q3 FY2020 | Sep 30, 2020 | $7.47M | -30.3% |
| Q2 FY2020 | Jun 30, 2020 | $6.99M | -22.5% |
| Q1 FY2020 | Mar 31, 2020 | $46.90M | +59.0% |
| Q4 FY2019 | Dec 31, 2019 | $8.28M | -27.8% |
| Q3 FY2019 | Sep 30, 2019 | $10.71M | -14.4% |
| Q2 FY2019 | Jun 30, 2019 | $9.01M | -57.8% |
| Q1 FY2019 | Mar 31, 2019 | $29.49M | +107.9% |
| Q4 FY2018 | Dec 31, 2018 | $11.47M | -57.6% |
| Q3 FY2018 | Sep 30, 2018 | $12.51M | -48.2% |
| Q2 FY2018 | Jun 30, 2018 | $21.34M | +143.8% |
| Q1 FY2018 | Mar 31, 2018 | $14.18M | +21.7% |
| Q4 FY2017 | Dec 31, 2017 | $27.07M | +331.7% |
| Q3 FY2017 | Sep 30, 2017 | $24.14M | +599.0% |
| Q2 FY2017 | Jun 30, 2017 | $8.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.65M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.27M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.45M | – |
See a number that looks wrong?